Rogers Communications Inc. (RCI) EPS Estimated At $0.68; Arena Pharmaceuticals, Inc. (ARNA) Covered By 5 Bulls

January 1, 2018 - By Ellis Scott

Among 7 analysts covering Arena Pharmaceuticals (NASDAQ:ARNA), 5 have Buy rating, 0 Sell and 2 Hold. Therefore 71% are positive. Arena Pharmaceuticals had 13 analyst reports since October 28, 2015 according to SRatingsIntel. The stock has “Outperform” rating by FBR Capital on Thursday, September 15. The firm has “Buy” rating given on Monday, July 17 by Leerink Swann. RBC Capital Markets maintained Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) on Wednesday, November 11 with “Sector Perform” rating. The stock of Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) earned “Buy” rating by Cantor Fitzgerald on Thursday, June 29. WallachBeth Capital maintained Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) rating on Wednesday, October 28. WallachBeth Capital has “Buy” rating and $4 target. Cantor Fitzgerald maintained the shares of ARNA in report on Wednesday, November 8 with “Buy” rating. The firm has “Buy” rating given on Wednesday, July 19 by Cantor Fitzgerald. Needham maintained Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) on Tuesday, August 8 with “Hold” rating. The firm has “Buy” rating given on Tuesday, July 11 by Cantor Fitzgerald. Citigroup maintained it with “Buy” rating and $37 target in Wednesday, July 12 report. See Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) latest ratings:

08/11/2017 Broker: Cantor Fitzgerald Rating: Buy New Target: $37.0 Maintain
08/08/2017 Broker: Needham Rating: Hold Maintain
19/07/2017 Broker: Cantor Fitzgerald Rating: Buy New Target: $37.0000 Maintain
17/07/2017 Broker: Leerink Swann Rating: Buy New Target: $53.0000 Maintain
12/07/2017 Broker: Citigroup Rating: Buy Old Target: $23 New Target: $37 Maintain
11/07/2017 Broker: Cantor Fitzgerald Rating: Buy New Target: $37.0000 Maintain

Analysts expect Rogers Communications Inc. (NYSE:RCI) to report $0.68 EPS on January, 25 before the open.They anticipate $0.16 EPS change or 30.77% from last quarter’s $0.52 EPS. RCI’s profit would be $354.63M giving it 18.72 P/E if the $0.68 EPS is correct. After having $0.81 EPS previously, Rogers Communications Inc.’s analysts see -16.05% EPS growth. It closed at $50.93 lastly. It is down 20.75% since January 1, 2017 and is uptrending. It has outperformed by 4.05% the S&P500.

Arena Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing novel small molecule drugs for various therapeutic areas in the United States and Switzerland. The company has market cap of $1.33 billion. The companyÂ’s proprietary investigational clinical programs include etrasimod , which is in Phase IIb evaluation for ulcerative colitis, as well as is in Phase IIa evaluation for dermatologic extraintestinal manifestations in inflammatory bowel disease, pyoderma gangrenosum, and primary biliary cholangitis; ralinepag that is in Phase IIb evaluation to treat pulmonary arterial hypertension; and APD371, which is in Phase IIa evaluation for the treatment of pain associated with Crohn's disease. It currently has negative earnings. It has collaboration agreements with Eisai Inc.; Eisai Co., Ltd.; Axovant Sciences Ltd.; and Boehringer Ingelheim International GmbH.

The stock decreased 1.93% or $0.67 during the last trading session, reaching $33.97. About 432,732 shares traded. Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) has declined 11.92% since January 1, 2017 and is downtrending. It has underperformed by 28.62% the S&P500.

Rogers Communications Inc. operates as a communications and media firm in Canada. The company has market cap of $26.56 billion. The companyÂ’s Wireless segment offers wireless telecommunications services to clients and businesses under the Rogers, Fido, and chatr brands; and wireless devices, services, and applications. It has a 26.32 P/E ratio. This segment distributes its products through independent dealer networks, company-owned retail stores, retail chains and convenience stores, ecommerce sites, call centers and outbound telemarketing, and other distribution channels.